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Background. Since the FEV1/FVC ratio declines with age, using the fixed ratio of 0.70 leads to overdiagnosis of COPD in older
populations and underdiagnosis among young adults. Objective. To evaluate whether discordant obstructive cases (FEV1/FVC <
0.70 but ≥LLN) are a healthy population or have clinical features that would place them at increased risk. Methods. We used
post-bronchodilator spirometry data from the population-based Austrian Burden of Obstructive Lung Disease (BOLD) study.
Those with post-bronchodilator FEV1/FVC ratio <LLN and <0.70 were defined as concordant obstructive cases. Participants with
post-bronchodilator FEV1/FVC ratio ≥LLN but <0.70 were defined as discordant obstructive cases. Results. Discordant obstructive
cases were more likely to be older, male and never-smokers. Additionally they had less respiratory symptoms and less severe
impairment of FEV1. However, discordant obstructive cases reported significantly more often a diagnosis of heart disease than
subjects with normal lung function (27.2% vs 7.3%, P = .015). Conclusion. The clinical profile of discordant obstructive cases
includes potentially important comorbid disease.

1. Introduction
Lung function measurements are recommended as essential
for diagnosing COPD and helpful for grading its severity
[1].
According to current GOLD guidelines [2], chronic
obstructive pulmonary disease is defined as airflow limitation with a postbronchodilator FEV1/FVC ratio below 70%.
On the one hand, these criteria have simplified the
diagnosis of COPD and have helped to improve the awareness of this disease. But on the other hand, the use of a
fixed threshold to define airways obstruction is associated
with some extent of misclassification. Since the FEV1/FVC
ratio declines with age, there is a risk of overdiagnosis of
COPD among healthy elderly people [3]. Because of this
misclassification problem, the American Thoracic Society/

European Respiratory Society guidelines [4] continue to
oﬃcially recommend an interpretative algorithm that uses
the 5th percentile lower limit of normal (LLN), which is agespecific and declines with age, to define pulmonary function
abnormalities.
For this study, we analyzed postbronchodilator spirometry data of an Austrian population-based survey in adults
aged 40 years and over. We compared the fixed ratio with
the lower limit of normal as a diagnostic criterion for
nonreversible airways obstruction. We tested the hypothesis
that discordant obstructive cases (FEV1/FVC < 0.70 and
≥LLN) are a healthy population (i.e., they are elderly,
asymptomatic subjects without the presence of known risk
factors for chronic airways obstruction) or whether these inbetween cases might represent subjects at risk who should be
followed carefully.
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2. Methods
2.1. Study Population. The study population consisted of
participants of the Austrian Burden of Obstructive Lung
Disease (BOLD) study [5]. In this study, a gender-stratified
random sample of the inhabitants of Salzburg County, aged
40 years and over, was surveyed. Of the 2,200 individuals
(1,100 men and 1,100 women) whom we attempted to
contact, 1,258 (60%) completed the full protocol and had
spirometry findings that met ATS quality control criteria (see
below). These individuals constitute the primary sample for
this analysis. The study was approved by the local Ethics
Committee of Salzburg County, and all participants gave
written informed consent.
2.2. Study Measures. Spirometry was done according to
American Thoracic Society (ATS) criteria [6] by trained and
certified technicians using the NDD Easy One spirometer
with participants in a seated position. Separate measurements were made before and at least 15 minutes after
two puﬀs of salbutamol (200 μg) metered dose inhaler,
administered using a Volumatic spacer. Spirometry data
were sent electronically to the Pulmonary Function Quality
Control Centre in Salt Lake City, Utah, USA, where each
spirogram was reviewed and graded using ATS guidelines
[6].
Only spirograms that met ATS acceptability and reproducibility criteria were included; at least three trials, two
acceptable (free from artefact, sudden stops, and back extrapolated volumes greater than 5.0% of FVC) and reproducible
(diﬀerence between largest and second largest values is less
than 200 mL) tests for both the forced expiratory volume
in one-second (FEV1 ) and the forced vital capacity (FVC).
Study technicians were continuously monitored. When a
technician’s quality score dropped below a preset level, he/she
had to stop testing and be retrained and recertified.
2.3. Questionnaire Data. The BOLD questionnaires included
information on respiratory symptoms, risk factors for
COPD, comorbidities, and respiratory diagnoses, and were
administered by a trained and certified staﬀ.
2.4. Definitions. Nonreversible “airways obstruction” was
defined either as a postbronchodilator FEV1/FVC ratio below
the lower limit of normal (LNN) or an FEV1/FVC ratio below
0.70 (according to GOLD criteria).
The NHANES III reference equations [7] were used to
calculate predicted values and LLNs for FEV1, FVC, and
FEV1/FVC. The Lower limit of normal (LLN) is based on the
lower fifth percentile of the index.
In the presence of an abnormal FEV1/FVC ratio, “severity
of airway obstruction” was graded as follows, possible normal
variant (FEV1 > 100% predicted), mild (FEV1 70–100%
predicted), moderate (FEV1 50–70% predicted), and severe
(FEV1 < 50% predicted).
Participants whose postbronchodilator FEV1/FVC ratio
was below both the LLN and the fixed ratio of 0.70 were
defined as “concordant obstructive cases”.
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Table 1: Population characteristics and postbronchodilator lung
function data (n = 1258).
Subjects, n (%)
Age distribution yrs, n (%)
40–50
51–60
61–70
71–80
81+
Body mass index [kg/(m2)],
mean (SD)
FVC (L), mean (%pred.)
FEV1 (L), mean (%pred.)
FEV1/FVC%, mean (%pred.)

Male
685 (54.5%)

Female
573 (45.5%)

206 (30.1%)
202 (29.5%)
169 (24.7%)
83 (12.1%)
25 (3.6%)

183 (31.9%)
175 (30.5%)
136 (23.7%)
57 (10.0%)
22 (3.9%)

26.7 (0.14)

26.1 (0.20)

4.5 (97.5%)
3.4 (95.0%)
74.1 (97.6%)

3.4 (100.6%)
2.5 (95.9%)
74.5 (95.5%)

Participants who had a postbronchodilator FEV1/FVC
ratio above the LLN but below the fixed ratio of 0.70 were
defined as “discordant obstructive cases”.
“Restrictive lung function” was defined as postbronchodilator FVC < 80% predicted and a FEV1/FVC > 70%.
“Doctor-diagnosed COPD” was defined as self-reported
physician’s diagnosis of chronic bronchitis, emphysema, or
COPD.
“Ever smoking” (current or former smoking) was defined
as smoking more than 20 packs of cigarettes in a lifetime
or more than 1 cigarette/day for a year. “Never smoking”
was defined as smoking less than 20 packs of cigarettes in a
lifetime.
Additional measures evaluated included self-report of
respiratory symptoms for “cough” (Do you usually cough
when you don’t have a cold?), “phlegm” (Do you usually bring
up phlegm from your chest, or do you usually have phlegm in
your chest that is diﬃcult to bring up when you don’t have a
cold?), and “dyspnea” (Are you troubled by shortness of breath
when hurrying on the level or walking up a slight hill?); and
“self-reported physician diagnosis” of asthma, tuberculosis,
heart disease, hypertension, diabetes, and stroke.
2.5. Statistical Analysis. Sensitivity and specificity of
FEV1/FVC < LLN for diagnosing airway obstruction defined
by FEV1/FVC < 0.70 were calculated using 2 × 2 tables.
Statistical significance of diﬀerences was evaluated using the
chi-square test and the nonparametric Wilcoxon test. All
statistical analyses were done with SAS 8.2 (SAS Institute,
Inc., Cary, NC).

3. Results
Of the 1349 participants with postbronchodilator spirometry, 1258 (93%) met the quality control criteria and
were included in this analysis. Population characteristics
and postbronchodilator lung function data of the study
population (n = 1258) are shown in Table 1.
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FEV1/FVC < 0.70
(n = 304)

FEV1/FVC ≥ 0.70
(n = 954)

90

192 (63.2%)

7 (0.7%)

112 (36.8%)

947 (99.3%)

FEV1/FVC < LLN
(n = 199)
FEV1/FVC ≥ LLN
(n = 1059)

FEV1/FVC (%)

Table 2: Airways obstruction defined by postbronchodilator FEV1/
FVC < 0.70 and FEV1/FVC < LLN.

80
70
60
40

Applying the current GOLD criteria (FEV1/FVC < 0.70)
to postbronchodilator spirometry, the prevalence of COPD
GOLD stage I or higher in our population-based sample
of adults aged 40 years and over was 24.2%. In contrast to
this, utilization of the lower limit of normal as a threshold
for the FEV1/FVC ratio (FEV1/FVC < LLN) demonstrated a
prevalence of 15.3%. Prevalence of doctor-diagnosed COPD
(reported physicians diagnosis of COPD, emphysema, or
chronic bronchitis) was 5.6%.
Figure 1 shows the declining FEV1/FVC ratio by age in
the study group without airways obstruction (n = 1059,
FEV1/FVC > LLN). The prevalence of COPD by diagnostic
definition and age group is illustrated in Figure 2. Sensitivity
and specificity of the widely used fixed ratio (0.70) compared
to the lower limit of normal are shown in Table 2.
Concordant obstructive cases (FEV1/FVC < 0.70 &
<LLN) showed a trend towards more severe airways obstruction than discordant obstructive cases (FEV1/FVC < 0.70 &
≥LLN), see Table 3. 89.3% of discordant obstructive cases
had a FEV1 greater than 70% of its predicted value, and none
of the discordant obstructive cases had a FEV1 less than 50%
of its predicted value.
Overall, 6.4% (n = 81) of the study population were
discordant obstructive cases (FEV1/FVC < 0.70 & ≥LLN)
with mild to moderate obstructive impairment (FEV1 100–
50% predicted). Concordant obstructive and discordant
obstructive cases with mild to moderate impairment of FEV1
diﬀered significantly in terms of age, gender, and reported
cough and phlegm (see Table 4). However, when adjustments
for age were made, they were very similar in terms of
comorbid disease, smoking status, and reported dyspnea (see
Table 4).
The clinical profile of subjects with discordant obstructive findings was similar to the profile of subjects with
restrictive lung function (see Table 4). In addition to this,
subjects with discordant obstructive findings (FEV1/FVC <
0.70 & ≥LLN) reported significantly more often a diagnosis
of heart disease than subjects with “normal” lung function
(FEV1/FVC > 0.70 & FVC ≥ 80% pred.), see Table 4.

4. Discussion
This population-based study contributes to the characterization of discordant obstructive cases (=subjects with
“normal” findings using the LLN but abnormal findings
using the fixed cutoﬀ of 70% as a threshold for the FEV1/FVC
ratio). The data suggest that subjects who are in between
the two definitions of airways obstruction may not have

50
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Figure 1: Study subjects with FEV1/FVC > LLN (n = 1059): relationship between FEV1/FVC% and age. Lines represent regression
of FEV1/FVC ratio by age (solid line) with 95% confidence limits for
mean predicted values (dotted lines). The horizontal line indicates
the 70% level of the FEV1/FVC ratio.
Prevalence of COPD per 1000 population
800
700
600
500
400
300
200
100
0

40–50

51–60
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Age (years)

71–80

>80

Fixed ratio
LLN
Doctor diagnosis

Figure 2: Prevalence of nonreversible airways obstruction with age,
using diﬀerent definitions (per 1000 population). “Fixed ratio”:
postbronchodilator FEV1/FVC < 0.70, “LLN”: postbronchodilator
FEV1/FVC < LLN, “doctor diagnosis”: prior physicians diagnosis of
COPD.

clinically significant airways obstruction. However, their
clinical profile is characterized by relevant comorbid disease
and is clearly diﬀerent from the profile of age-matched
subjects with “normal” lung function.
4.1. The Discrepancy between the Diﬀerent Definitions. The
discrepancy in the prevalence of airways obstruction depending on the criteria used to define disease is consistent with
other studies.
A similar diﬀerence in the prevalence of COPD depending on the definition used was reported for adults aged
40 years and over in New Zealand, showing a GOLDdefined prevalence of COPD of 14.2% and a LLN-defined
prevalence of 9.0% [8]. A recent study based on spirometry
tests from a regional primary care diagnostic centre in the
Netherlands has shown that the discrepancy between the
two definitions for airflow obstruction increases along with
age, and that utilization of the fixed FEV1/FVC cutoﬀ may
cause substantial COPD overdiagnosis in primary care [9].
In an elderly Chinese population (subjects aged 60 years and
above), the prevalence of airways obstruction using the fixed
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Table 3: Severity of airways obstruction in concordant and discordant obstructive cases.

Severity of airways obstruction

Concordant obstructive cases§
(n = 192)

Discordant obstructive
cases# (n = 112)

P-value

22 (11.4%)
115 (59.9%)
41 (21.4%)
14 (7.3%)

31 (27.7%)
69 (61.6%)
12 (10.7%)
0 (0.0%)

<.001
<.001
.003
/

Possible normal variant (FEV1 >100% predicted)
Mild obstruction (FEV1 70%–100% predicted)
Moderate obstruction (FEV1 50%–70% predicted)
Severe obstruction (FEV1 < 50% predicted)
§

Concordant obstructive cases: FEV1/FVC < 0.70 & <LLN.
obstructive cases: FEV1/FVC < 0.70 & ≥LLN.

# Discordant

Table 4: Characteristics of subjects with discordant obstructive findings and comparison to subjects with normal lung function, subjects
with restrictive lung function and subjects with concordant obstructive findings. Presented obstructive cases are limited to those with mild
to moderate impairment of FEV1 (FEV1 50%–100% pred.).

Characteristics
Age, mean (SE)
Sex, male
Never smoker
Respiratory
Symptomsφ
Cough
Phlegm
Dyspnea
Comorbiditiesφ
Asthma
Heart disease
Hypertension
Diabetes
Stroke
Tuberculosis

Discordant
obstructive
cases# (n = 81)

“Normal” lung
function$
(n = 414)

Restrictive lung
functionΨ
(n = 82)

Concordant
obstructive
cases§ (n = 156)

P-value∗

P-value∗∗

P-value∗∗∗

67 (0.99)
66 (81.5%)
33 (40.7%)

54.8 (0.50)
230 (55.6%)
203 (49.0%)

59.4 (1.16)
48 (58.5%)
35 (42.7%)

60.5 (0.95)
76 (48.7%)
45 (28.9%)

<.001
<.001
.172

<.001
.002
.802

<.001
<.001
.065

14 (17.3%)
20 (24.7%)
24 (29.6%)

60 (14.5%)
88 (21.3%)
62 (15.0%)

19 (23.2%)
23 (28.1%)
29 (35.4%)

51 (32.7%)
65 (41.7%)
41 (26.3%)

.796
.893
.085

.291
.442
.084

.009
.004
.987

7 (8.6%)
22 (27.2%)
33 (40.7%)
10 (12.4%)
6 (7.4%)
2 (2.5%)

29 (7.0%)
30 (7.3%)
135 (32.6%)
32 (7.7%)
6 (1.5%)
10 (2.4%)

5 (6.1%)
19 (23.2%)
29 (35.4%)
8 (9.8%)
4 (4.9%)
2 (2.4%)

21 (13.5%)
23 (14.7%)
55 (35.3%)
10 (6.4%)
3 (1.9%)
8 (5.1%)

.116
.015
.223
.661
.228
.479

.172
.179
.970
.538
.643
.929

.585
.450
.689
.343
.156
.195

#

Discordant obstructive cases: FEV1/FVC < 0.70 & ≥LLN.
obstructive cases: FEV1/FVC < 0.70 & <LLN.
$ Normal lung function: FEV1/FVC > 0.70 & FVC ≥ 80% pred.
Ψ Restrictive lung function: FEV1FVC > 0.70 & FVC < 80% pred.
φ Results adjusted for age.
∗ P-value for diﬀerence between “discordant obstructive cases” and “normal lung function”.
∗∗ P-value for diﬀerence between “discordant obstructive cases” and “restrictive lung function”.
∗∗∗ P-value for diﬀerences between “discordant obstructive cases” and “concordant obstructive cases”.
§ Concordant

ratio of 0.70 or using the LLN for the postbronchodilator
FEV1/FVC ratio was 25.9% and 12.4%, respectively [10].
A population-based study in Norway using prebronchodilator spirometry data has shown that a FEV1/FVC
ratio below 0.70 was 50% more frequent in women aged 70
years and above compared to women aged 60–69 years. The
corresponding increase in men was 80%. On the basis of their
results, the authors suggested the use of a threshold of 65%
(FEV1/FVC < 0.65) for subjects over the age of 70 years [11].
However, the discrepancy depending on the definition
used shows that either the GOLD criteria lead to a relevant

percentage of false positives or utilization of the lower limit
of normal to a relevant percentage of false negatives.
In general, any diagnostic test should have both high
sensitivity and high specificity. Since the FEV1/FVC ratio
declines with age, the fixed ratio of 0.70 which is recommended by the GOLD Initiative, may lead to considerable
overdiagnosis among healthy elderly people and underdiagnosis among young adults with early disease [3, 12–15]. The
problem of misclassification might be pronounced in the
primary care setting, where early stages of disease are seen.
Therefore, utilization of the lower limit of normal instead
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of a fixed ratio has been especially recommended for COPD
screening in primary care [16].
4.2. Pros and Cons of the Diﬀerent Definitions. While utilization of the fixed ratio (0.70) is simple, convenient, and independent from the existence of adequate reference equations
and specially adapted spirometers, the use of the age- and
sex-specific LLN as a threshold for the FEV1/FVC ratio may
lessen the risk of overdiagnosis of airways obstruction among
the elderly and underdiagnosis among young adults.
Utilization of GOLD guidelines and unreflective interpretation of test results may have negative consequences by
misclassifying healthy elderly subjects as COPD and thus
possibly causing unnecessary treatment and healthcare costs.
With this and other critical issues in mind, a growing number
of experts recommend to replace the 0.70 threshold with the
lower limit of normal threshold [17].
4.3. Discordant Obstructive Cases (In-Between Cases). When
one definition of airways obstruction (FEV1/FVC < LLN)
is thought to replace another definition (FEV1/FVC < 0.70)
the main point of interest is of course the number and
characteristics of those subjects who have discordant findings
(“normal” using the LLN but “abnormal” using the fixed
ratio).
The comparison of concordant obstructive (FEV1/FVC <
0.70 & <LLN) cases and discordant obstructive (FEV1/FVC <
0.70 & ≥LLN) cases revealed that subjects in the latter
group were significantly older and significantly more likely
to be male. In addition to this, discordant obstructive cases
reported less active smoking and less respiratory symptoms.
Our data suggest that utilization of the LNN as a threshold
for the FEV1/FVC ratio helps to identify clinically significant
disease.
However, the clinical profile of cases in between the two
definitions (discordant obstructive cases FEV1/FVC < 0.70
& ≥LLN) was characterized by high amounts of comorbid
disease. When adjustments for age were made, subjects with
discordant obstructive findings reported significantly more
often a diagnosis of heart disease than subjects with normal
lung function. The clinical profile of subjects with discordant
obstructive findings was very similar to the profile of subjects
with restrictive lung function. Therefore, this data suggest
that a proportion of individuals with discordant obstructive
findings may have clinically important comorbidities. Results
of a cohort study of the Cardiovascular Health Study have
shown that subjects classified as “normal” using the LLN
but abnormal using the GOLD criteria (0.70) were more
likely to die and to have a COPD-related hospitalization
during followup. The authors suggested that a fixed ratio of
less than 0.70 identifies at-risk patients, even among older
adults [18]. In an editorial on the definition of COPD the
author suggested that a finding that predicts a bad event or
premature death may probably represent “disease” [19].
4.4. Definition of Airways Obstruction and Underdiagnosis.
Besides the valuable discussion on what might be the
most precise definition of airways obstruction, one has
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to take into consideration that currently the majority of
disease is still undiagnosed and untreated. The prevalence
of physician-diagnosed chronic airways obstruction in our
study population was 5.6%. This is far below both the
prevalence defined by postbronchodilator FEV1/FVC < 0.70
(24.2%) and FEV1/FVC < LLN (15.3%). A recent study in
a primary care setting in Poland has shown that only 18.6%
of subjects with COPD had previously been diagnosed [20].
Overall, about 8%–13% of people in general population
surveys have airways obstruction without having a diagnosis
of obstructive lung disease [21].
4.5. Limitations. Limitations of our study include the use
of reference equations from the United States that may
not ideally apply to our population. However, using either
the NHANES III predictions or predictions based on the
study sample gave the same high COPD prevalence [5].
Another potential limitation of our study is that 200 mcg of
salbutamol was administered instead of 400 mcg, as recommended by the GOLD guidelines. The prevalence of postBD airway obstruction would have been slightly lower with
a higher dose of BD. However, many pulmonary function
laboratories have been using 200 mcg and we worried about
the risk of arrhythmias in our field settings. The timing of
the postbronchodilator spirometry only 15 minutes after the
administration of salbutamol, while standard practice, may
nonetheless underestimate the true bronchodilator response
which may not be evident for 30–60 minutes.

5. Conclusion
The lower limit of normal (LLN) seems to be the more
reasonable threshold to define clinically significant airways
obstruction. The risk of substantial overdiagnosis of COPD
and subsequent unnecessary treatment and healthcare costs
(due to utilization of a simple fixed threshold) is pitted
against the reasonable desire for simplicity.
The results of this study indicate that subjects who
are in between the two definitions of airways obstruction
(discordant obstructive cases, FEV1/FVC < 0.70 & ≥LLN) do
not have clinically significant airways obstruction. However,
their clinical profile is characterized by relevant comorbid
disease and, therefore, they might be at risk and should be
followed carefully.
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